| Literature DB >> 32001210 |
Cornelius A Omatola1, Bernard A Onoja2, Peter K Fassan3, Stephanie A Osaruyi3, Mercy Iyeh3, Matthew A Samuel3, Peace U Haruna3.
Abstract
Febrile illnesses in developing countries are often misdiagnosed as malaria or typhoid fever. Although arboviral infections have similar clinical symptoms, they are usually not screened because of limited resources and the fact that there are several viruses in this group. Chikungunya virus (CHIKV) has been isolated in parts of Nigeria, but there is no documented evidence of the infection in Kogi State. This study determined seroprevalence of active and past CHIKV infection among febrile patients who tested negative for malaria and typhoid fever. Sera from 243 febrile patients were screened for CHIKV IgG and IgM using an immunochromatographic test kit. Clinical and socio-demographic variables were collected using a structured questionnaire. Recent CHIKV infection was observed in 5.8% of the study participants while 25.1% had IgG antibodies demonstrating previous infection. Significant associations were observed between seropositivity and age of participants (p<0.001), sex (p=0.044), marital status (p=0.002), and occupation (p<0.001). Clinical symptoms such as fever, joint pain, and headache were significantly associated with seropositivity. This study identified recent CHIKV infection in Anyigba. Therefore, there is need for routine screening of febrile patients and molecular characterization to determine the nature of circulating strains.Entities:
Keywords: Chikungunya; Fever; IgG; IgM; Nigeria; Seroprevalence
Mesh:
Substances:
Year: 2020 PMID: 32001210 PMCID: PMC9392021 DOI: 10.1016/j.bjid.2020.01.001
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Anti-CHIKV antibodies and its distribution in relation to sex, age and location of study participants.
| Variable | No. of Participant | Proportion %) | No.%) of specific anti-CHIKV-Abs | Total anti-CHIKV-Abs | |||||
|---|---|---|---|---|---|---|---|---|---|
| IgM only | IgG only | IgM+IgG | |||||||
| Male | 110 | 45.3 | 8 (7.3) | 32 (29.1) | 5 (4.5) | 45 (40.9) | |||
| Female | 133 | 54.7 | 6 (4.5) | 29 (21.8) | 3 (2.3) | 38 (28.6) | |||
| Total | 243 | 100 | 14 (5.8) | 61 (25.1) | 8 (3.3) | 83 (34.2) | |||
| X2 | 4.075 | ||||||||
| P-value | 0.044 | ||||||||
| 5–14 | 37 | 15.2 | 1 (2.7) | 1 (2.7) | 0 (0.0) | 2 (5.4) | |||
| 15-29 | 75 | 30.9 | 3 (4.0) | 13 (17.3) | 1 (1.3) | 17 (22.7) | |||
| 30–44 | 83 | 34.2 | 6 (7.2) | 31 (37.3) | 4 (4.8) | 41 (49.4) | |||
| 45-59 | 26 | 10.7 | 3 (11.5) | 7 (26.9) | 1 (3.8) | 11 (42.3) | |||
| 60–74 | 16 | 6.6 | 0 (0.0) | 7 (43.8) | 2 (12.5) | 9 (56.3) | |||
| 75–80 | 06 | 2.5 | 1 (16.7) | 2 (33.3) | 0 (0.0) | 3 (50.0) | |||
| Total | 243 | 100 | 14 (5.8) | 61 (25.1) | 8 (3.3) | 83 (34.2) | |||
| X2 | 31.485 | ||||||||
| P-value | 0.000 | ||||||||
| KSUTH | 36 | 14.8 | 0 (0.0) | 13 (36.1) | 0 (0.0) | 13 (36.1) | |||
| MGH | 75 | 30.9 | 3 (4.0) | 19 (25.3) | 2 (2.7) | 24 (32.0) | |||
| PH | 39 | 16.0 | 2 (5.1) | 5 (12.8) | 4 (10.3) | 11 (28.2) | |||
| GCH | 3 | 21.8 | 6 (11.3) | 11 (20.8) | 0 (0.0) | 17 (32.1) | |||
| CGCH | 40 | 16.5 | 3 (7.5) | 13 (32.5) | 2 (5.0) | 18 (45.0) | |||
| Total | 243 | 100 | 14 (5.8) | 61 (25.1) | 8 (3.3) | 83 (34.2) | |||
| X2 | 3.02 | ||||||||
| P-value | 0.55 | ||||||||
Key: KSUTH = Kogi State University Hospital; MGH = Maria Gorethi Hospital; PH = Peace Hospital; GCH = Grimard Catholic Hospital, CGCH = Christ the Good shepherd Hospital; Abs = Antibodies; X2 = Chi square value.
Fig. 1Prevalence of CHIKV antibodies in febrile patients in Anyigba according to age group.
Socio-demographic characteristics of patients with active/recent and previous CHIKV infection.
| Variable | No. Tested | Total No. (%) of anti-CHIKV-Abs | P-value | No. (%) of IgM/ IgM+IgG positive | P-value | No. (%) of IgG positive | P-value |
|---|---|---|---|---|---|---|---|
| None | 40 | 13(32.5) | 0.43 | 4 (10.0) | 0.99 | 9 (0.23) | 0.30 |
| Primary | 32 | 7 (21.9) | 3 (9.4) | 4 (0.13) | |||
| Secondary | 82 | 30 (36.6) | 7 (8.5) | 23 (0.28) | |||
| Tertiary | 89 | 33 (37.1) | 8 (9.0) | 25 (0.28) | |||
| Married | 112 | 51 (45.5) | 13 (11.6) | 38 (0.34) | |||
| Divorced | 16 | 7 (43.8) | 0.002 | 2 (12.5) | 0.49 | 5 (0.31) | 0.01 |
| Widowed | 22 | 6 (27.3) | 1 (4.5) | 5 (0.23) | |||
| Single | 93 | 19 (20.4) | 6 (6.5) | 13 (0.14) | |||
| Farming | 52 | 25 (48.1) | 8 (15.4) | 17(0.33) | |||
| Civil servants | 39 | 15 (38.5) | 0.000 | 2 (5.1) | 0.25 | 13 (0.33) | 0.003 |
| Business | 59 | 26 (44.1) | 6 (10.2) | 20 (0.34) | |||
| Students | 93 | 17 (18.3) | 6 (6.5) | 11 (0.12) | |||
| Yes | 113 | 47 (41.6) | 13 (11.5) | 0.26 | 34 (0.30) | 0.10 | |
| No | 130 | 38 (29.2) | 0.023 | 9 (6.9) | 27 (0.21) |
Clinical manifestations in patients with anti-CHIKV IgM antibody.
| Symptoms | No. Tested | No. (%) positive | Odd ratio (OR) | 95% CI | P-value |
|---|---|---|---|---|---|
| Fever | |||||
| Yes | 194 | 15 (7.7) | |||
| No | 49 | 7 (14.3) | 0.5 | 0.193–1.311 | 0.153 |
| Rash | |||||
| Yes | 15 | 0 (0.0) | |||
| No | 228 | 22 (9.6) | – | – | 0.207 |
| Nausea | |||||
| Yes | 67 | 3 (4.5) | |||
| No | 176 | 19 (10.8) | 0.4 | 0.111–1.354 | 0.125 |
| Headache | |||||
| Yes | 169 | 14 (8.3) | |||
| No | 74 | 8 (10.8) | 0.7 | 0.298–1.861 | 0.528 |
| Joint pain | |||||
| Yes | 124 | 10 (8.1) | |||
| No | 119 | 12 (10.1) | 0.8 | 0.325–1.885 | 0.583 |
| Abdominal pain | |||||
| Yes | 97 | 10 (10.3) | |||
| No | 146 | 12 (8.2) | 1.2 | 0.532–3.099 | 0.578 |
| Diarrhea | |||||
| Yes | 42 | 4 (9.5) | |||
| No | 201 | 18 (9.0) | 1.1 | 0.343–3.341 | 0.907 |
| Fever +Headache | |||||
| Yes | 141 | 12 (8.5) | |||
| No | 102 | 10 (9.5) | 0.9 | 0.355–2.065 | 0.729 |
| Fever +Joint Pain | |||||
| Yes | 106 | 7 (6.6) | |||
| No | 137 | 15 (10.9) | 0.6 | 0.226–1.466 | 0.242 |
| Fever +Abdominal Pain | |||||
| Yes | 83 | 9 (10.8) | |||
| No | 160 | 13 (8.1) | 1.4 | 0.562–3.364 | 0.484 |